What Happened?
Shares of fertility benefits company Progyny (NASDAQ: PGNY) jumped 3.5% in the afternoon session after KeyBanc raised its price target on the stock to $35 from $30, citing expectations of a strong earnings report and increased future guidance.
The investment bank, which maintained its "Overweight" rating, pointed to an acceleration in transactions and spending during June as the basis for its positive outlook. KeyBanc's action followed other recent bullish calls from Wall Street. Truist Securities also raised its price target, and Canaccord Genuity upgraded Progyny's stock rating to "Buy" from "Hold," signaling growing analyst confidence in the company's performance.
The shares were trading at $31.73, up 3.5% from the previous close.
Is now the time to buy Progyny? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Progyny’s shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 5 months ago when the stock dropped 22% on the news that it issued a weak financial outlook for 2026 that overshadowed its fourth-quarter results.
The company's guidance for the first quarter of 2026 projected revenue of $325.5 million, falling 5.1% short of Wall Street's expectations. Furthermore, the full-year forecast for 2026 was also disappointing, with both its adjusted earnings per share and EBITDA guidance missing analyst estimates. This downbeat forecast soured investor sentiment despite Progyny reporting strong fourth-quarter 2025 results. For that period, the company's revenue of $318.4 million grew 6.7% year-over-year and beat expectations, while its adjusted earnings per share of $0.48 came in nearly 20% ahead of consensus estimates. Ultimately, the market focused on the weaker-than-expected projections, signaling concerns about future growth.
Progyny is up 23.3% since the beginning of the year, and at $31.73 per share, it has set a new 52-week high. Despite the year-to-date gain, investors who bought $1,000 worth of Progyny’s shares 5 years ago would now be looking at only $556.87.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
